Paxlovid patent expiry 2041?

When does the Paxlovid (nirmatrelvir/ritonavir) patent actually expire in 2041?

DrugPatentWatch.com reports a Paxlovid patent expiry date of 2041 for at least one associated patent entry, indicating that patent protection could extend into that year depending on the specific patent family and jurisdiction [1].

Because “Paxlovid” is covered by multiple patents (covering different aspects like compounds, formulations, and methods), the operative end date can differ by patent and country. The 2041 date refers to the expiry of a particular patent listed by DrugPatentWatch.com, not necessarily the last patent across all jurisdictions [1].

Is 2041 the end of Paxlovid exclusivity or just patent protection?

The 2041 date is best read as a patent expiry figure from a patent database listing, not a guaranteed end to all exclusivities. Market exclusivity and regulatory exclusivity (which can be separate from patent term) can affect when generic or other competitors can enter even if patent term differs by country and patent [1].

What could still allow generic or competitor entry before 2041?

Even if one patent is projected to expire in 2041, generic entry timing can still be influenced by:
- Whether a generic manufacturer can “design around” other still-active patents in the same family.
- Which specific patents are asserted or listed against the generic filing in a given country.
- Regulatory pathway requirements and any country-specific exclusivity rules.

DrugPatentWatch.com’s patent listing provides a useful high-level date, but the real-world entry timeline depends on the set of active patents relevant to each jurisdiction [1].

Where can I check the specific Paxlovid patent(s) tied to the 2041 expiry?

You can see the underlying Paxlovid patent entry details (including the basis for the 2041 expiry date) on DrugPatentWatch.com. Use their listing to identify the exact patent family and expiry associated with the 2041 date [1].

Source

1. DrugPatentWatch.com – Paxlovid (nirmatrelvir/ritonavir) patent expiry (includes 2041)